Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Immune Checkpoint Inhibitor mediated Thyroiditis.

Iyer PC, Cabanillas M, Waguespack SG, Hu MI, Thosani SN, Lavis VR, Busaidy N, Subudhi SK, Diab A, Dadu R.

Thyroid. 2018 Aug 22. doi: 10.1089/thy.2018.0116. [Epub ahead of print]

PMID:
30132401
2.

Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.

Arudra K, Patel R, Tetzlaff MT, Hymes S, Subbiah V, Meric-Bernstam F, Torres-Cabala C, Aung PP, Nagarajan P, Diab A, Prieto VG, Nelson K, Curry JL.

J Cutan Pathol. 2018 Oct;45(10):786-790. doi: 10.1111/cup.13319. Epub 2018 Aug 3.

PMID:
30021048
3.

Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.

Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL.

J Cutan Pathol. 2018 Oct;45(10):764-773. doi: 10.1111/cup.13312. Epub 2018 Jul 24.

PMID:
29943453
4.

Temporal Trends in the Outcomes of Dialysis Patients Admitted With Acute Ischemic Stroke.

Alqahtani F, Berzingi CO, Aljohani S, Al Hajji M, Diab A, Alvi M, Boobes K, Alkhouli M.

J Am Heart Assoc. 2018 Jun 15;7(12). pii: e008686. doi: 10.1161/JAHA.118.008686.

5.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

PMID:
29848573
6.

Metastatic Melanoma of the Optic Nerve Sheath.

D'souza NM, Nguyen HD, Smith SV, Nagarajan P, Diab A, Allen RC, Gombos DS, Lee AG.

Neuroophthalmology. 2017 Sep 14;42(3):187-190. doi: 10.1080/01658107.2017.1372488. eCollection 2018 Jun.

7.

Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.

Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, Li A, Younes AI, Cadena A, Cushman TR, Chang JY, Nguyen QN, Gomez DR, Diab A, Heymach JV, Hwu P, Cortez MA, Welsh JW.

Clin Cancer Res. 2018 May 21. doi: 10.1158/1078-0432.CCR-17-3279. [Epub ahead of print]

PMID:
29784675
8.

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.

Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A.

J Immunother Cancer. 2018 May 11;6(1):37. doi: 10.1186/s40425-018-0346-6.

9.

Transcatheter Closure of a Sinus Venosus Atrial Septal Defect Via Transhepatic Access.

Alkhouli M, Campsey DM, Higgins L, Badhwar V, Diab A, Sengupta PP.

JACC Cardiovasc Interv. 2018 Jul 23;11(14):e113-e115. doi: 10.1016/j.jcin.2018.02.021. Epub 2018 May 2. No abstract available.

PMID:
29730369
10.

Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.

Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, Zobniw C, Johnson DH, Samdani R, Lum P, Shuttlesworth G, Blechacz B, Bresalier R, Miller E, Thirumurthi S, Richards D, Raju G, Stroehlein J, Diab A.

Inflamm Bowel Dis. 2018 Jul 12;24(8):1695-1705. doi: 10.1093/ibd/izy104.

PMID:
29718308
11.

Comparative and molecular analysis of MRSA isolates from infection sites and carrier colonization sites.

Alkharsah KR, Rehman S, Alkhamis F, Alnimr A, Diab A, Al-Ali AK.

Ann Clin Microbiol Antimicrob. 2018 Mar 15;17(1):7. doi: 10.1186/s12941-018-0260-2.

12.

A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.

Méndez E, Rodriguez CP, Kao MC, Raju S, Diab A, Harbison RA, Konnick EQ, Mugundu GM, Santana-Davila R, Martins R, Futran ND, Chow LQM.

Clin Cancer Res. 2018 Jun 15;24(12):2740-2748. doi: 10.1158/1078-0432.CCR-17-3796. Epub 2018 Mar 13.

PMID:
29535125
13.

The Genetics of Usher Syndrome in the Israeli and Palestinian Populations.

Khalaileh A, Abu-Diab A, Ben-Yosef T, Raas-Rothschild A, Lerer I, Alswaiti Y, Chowers I, Banin E, Sharon D, Khateb S.

Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):1095-1104. doi: 10.1167/iovs.17-22817.

PMID:
29490346
14.

Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.

Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL.

J Immunother Cancer. 2018 Feb 12;6(1):14. doi: 10.1186/s40425-018-0323-0.

15.

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.

Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL Jr, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA.

ESMO Open. 2018 Jan 24;3(1):e000283. doi: 10.1136/esmoopen-2017-000283. eCollection 2018.

16.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
17.

Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.

Morikawa A, Wang R, Patil S, Diab A, Yang J, Hudis CA, McArthur HL, Beal K, Seidman AD.

Clin Breast Cancer. 2017 Dec 21. pii: S1526-8209(17)30394-4. doi: 10.1016/j.clbc.2017.12.009. [Epub ahead of print]

PMID:
29337140
18.

The polarity protein Angiomotin p130 controls dendritic spine maturation.

Wigerius M, Quinn D, Diab A, Clattenburg L, Kolar A, Qi J, Krueger SR, Fawcett JP.

J Cell Biol. 2018 Feb 5;217(2):715-730. doi: 10.1083/jcb.201705184. Epub 2018 Jan 9.

19.

Whole-exome sequencing reveals POC5 as a novel gene associated with autosomal recessive retinitis pigmentosa.

Weisz Hubshman M, Broekman S, van Wijk E, Cremers F, Abu-Diab A, Khateb S, Tzur S, Lagovsky I, Smirin-Yosef P, Sharon D, Haer-Wigman L, Banin E, Basel-Vanagaite L, de Vrieze E.

Hum Mol Genet. 2018 Feb 15;27(4):614-624. doi: 10.1093/hmg/ddx428.

PMID:
29272404
20.

The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals.

Diab A, Foca A, Zoulim F, Durantel D, Andrisani O.

Antiviral Res. 2018 Jan;149:211-220. doi: 10.1016/j.antiviral.2017.11.015. Epub 2017 Nov 26. Review.

PMID:
29183719
21.

Evaluation of Mir-224, Mir-215 and Mir-143 as Serum Biomarkers for HCV Associated Hepatocellular Carcinoma

Mamdouh S, Khorshed F, Aboushousha T, Hamdy H, Diab A, Seleem M, Saber M.

Asian Pac J Cancer Prev. 2017 Nov 26;18(11):3167-3171.

22.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

23.

Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.

Mauzo SH, Tetzlaff MT, Nelson K, Amaria R, Patel S, Aung PP, Nagarajan P, Torres-Cabala CA, Diab A, Prieto VG, Curry JL.

Int J Dermatol. 2017 Nov 20. doi: 10.1111/ijd.13833. [Epub ahead of print]

PMID:
29152725
24.

Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.

Singh M, Vianden C, Cantwell MJ, Dai Z, Xiao Z, Sharma M, Khong H, Jaiswal AR, Faak F, Hailemichael Y, Janssen LME, Bharadwaj U, Curran MA, Diab A, Bassett RL, Tweardy DJ, Hwu P, Overwijk WW.

Nat Commun. 2017 Nov 13;8(1):1447. doi: 10.1038/s41467-017-01572-7.

25.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

26.

Variation-based sparse source imaging in localizing uterine activity.

Zahran S, Yochum M, Diab A, Zahran S, Marque C.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:2948-2951. doi: 10.1109/EMBC.2017.8037475.

PMID:
29060516
27.

Experts' Results in Blunt Thoracic Aortic Injury are Reproducible in Lower Volume Tertiary Institutions. Early and Mid-term Results of an Observational Study.

Ghazy T, Mikulasch S, Reeps C, Hoffmann RT, Wijatkowska K, Diab AH, Kappert U, Matschke K, Weiss N, Mahlmann A.

Eur J Vasc Endovasc Surg. 2017 Nov;54(5):604-612. doi: 10.1016/j.ejvs.2017.08.009. Epub 2017 Sep 25.

PMID:
28958467
28.

Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.

Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL.

J Cutan Pathol. 2017 Dec;44(12):1080-1086. doi: 10.1111/cup.13044. Epub 2017 Oct 13.

PMID:
28901560
29.

Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.

Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, Johnson DH, Uemura M, Diab A.

Ann Rheum Dis. 2017 Dec;76(12):2061-2064. doi: 10.1136/annrheumdis-2017-211560. Epub 2017 Aug 22.

PMID:
28830882
30.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

31.

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.

Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS.

J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. Review.

32.

Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.

Diab A, Foca A, Fusil F, Lahlali T, Jalaguier P, Amirache F, N'Guyen L, Isorce N, Cosset FL, Zoulim F, Andrisani O, Durantel D.

Hepatology. 2017 Dec;66(6):1750-1765. doi: 10.1002/hep.29236. Epub 2017 Nov 6.

33.

Does rehabilitation of cervical lordosis influence sagittal cervical spine flexion extension kinematics in cervical spondylotic radiculopathy subjects?

Moustafa IM, Diab AAM, Hegazy FA, Harrison DE.

J Back Musculoskelet Rehabil. 2017;30(4):937-941. doi: 10.3233/BMR-150464.

PMID:
28372313
34.

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA.

Sci Transl Med. 2017 Mar 1;9(379). pii: eaah3560. doi: 10.1126/scitranslmed.aah3560. Erratum in: Sci Transl Med. 2017 Apr 12;9(385):.

35.

Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.

Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL.

Am J Dermatopathol. 2017 Feb;39(2):121-129. doi: 10.1097/DAD.0000000000000688.

PMID:
28134729
36.

Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

Uemura M, Fa'ak F, Haymaker C, McQuail N, Sirmans E, Hudgens CW, Barbara L, Bernatchez C, Curry JL, Hwu P, Tetzlaff MT, Diab A.

J Immunother Cancer. 2017 Jan 18;5:7. doi: 10.1186/s40425-017-0208-7. eCollection 2017.

37.

Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.

Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A.

Arthritis Rheumatol. 2017 Apr;69(4):687-699. doi: 10.1002/art.40043. Epub 2017 Mar 3. Review. No abstract available.

38.

Inferior vena cava involvement in children with Wilms tumor.

Al Diab A, Hirmas N, Almousa A, Abu-Hijlih R, Aljlouni F, Sultan I, Ghandour K.

Pediatr Surg Int. 2017 May;33(5):569-573. doi: 10.1007/s00383-016-4034-7. Epub 2017 Jan 9.

PMID:
28070651
39.

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A.

Cancer Immunol Res. 2017 Feb;5(2):100-105. doi: 10.1158/2326-6066.CIR-16-0223. Epub 2017 Jan 6.

40.

Level I lymph node involvement in patients with N1b papillary thyroid carcinoma: a prospective study.

Eweida AM, Sakr MF, Hamza Y, Khalil MR, Gabr E, Koraitim T, Al-Wagih HF, Abo-Elwafa W, Ezzat Abdel-Aziz T, Diab AA, El-Sabaa B, Nabawi AS.

Eur Arch Otorhinolaryngol. 2017 Apr;274(4):1951-1958. doi: 10.1007/s00405-016-4423-5. Epub 2016 Dec 20.

PMID:
27999997
41.

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.

Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG.

J Cutan Pathol. 2017 Feb;44(2):158-176. doi: 10.1111/cup.12858. Epub 2016 Dec 21. Review.

PMID:
27859479
42.

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.

McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L.

Clin Cancer Res. 2016 Dec 1;22(23):5729-5737. Epub 2016 Aug 26.

43.

DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection.

Fan H, Cui Z, Zhang H, Mani SK, Diab A, Lefrancois L, Fares N, Merle P, Andrisani O.

Oncogene. 2017 Apr 27;36(17):2435-2445. doi: 10.1038/onc.2016.399. Epub 2016 Oct 31.

44.

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.

Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS.

Clin Cancer Res. 2017 Mar 15;23(6):1388-1396. doi: 10.1158/1078-0432.CCR-16-1432. Epub 2016 Sep 20.

45.

Addition of a Sagittal Cervical Posture Corrective Orthotic Device to a Multimodal Rehabilitation Program Improves Short- and Long-Term Outcomes in Patients With Discogenic Cervical Radiculopathy.

Moustafa IM, Diab AA, Taha S, Harrison DE.

Arch Phys Med Rehabil. 2016 Dec;97(12):2034-2044. doi: 10.1016/j.apmr.2016.07.022. Epub 2016 Aug 27.

PMID:
27576192
46.

EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes.

Mani SK, Zhang H, Diab A, Pascuzzi PE, Lefrançois L, Fares N, Bancel B, Merle P, Andrisani O.

J Hepatol. 2016 Nov;65(5):888-898. doi: 10.1016/j.jhep.2016.05.022. Epub 2016 May 26.

47.

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

Uemura M, Fa'ak F, Haymaker C, McQuail N, Sirmans E, Hudgens CW, Barbara L, Bernatchez C, Curry JL, Hwu P, Tetzlaff MT, Diab A.

J Immunother Cancer. 2016 Sep 20;4:55. doi: 10.1186/s40425-016-0157-6. eCollection 2016. Erratum in: J Immunother Cancer. 2017 Jan 18;5:7.

48.

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report.

Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A.

J Hematol Oncol. 2016 Sep 5;9(1):81. doi: 10.1186/s13045-016-0309-7.

49.

Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.

Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris E, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, McArthur HL.

Cancer Immunol Res. 2016 Oct;4(10):835-844. Epub 2016 Sep 1. Erratum in: Cancer Immunol Res. 2017 Mar;5(3):269.

50.

The effect of normalizing the sagittal cervical configuration on dizziness, neck pain, and cervicocephalic kinesthetic sensibility: a 1-year randomized controlled study.

Moustafa IM, Diab AA, Harrison DE.

Eur J Phys Rehabil Med. 2017 Feb;53(1):57-71. doi: 10.23736/S1973-9087.16.04179-4. Epub 2016 Aug 30.

Supplemental Content

Support Center